

**RESPONSE TO CBER COMMUNICATION REGARDING CLINICAL TOPICS (IR #17)
RECEIVED ON DECEMBER 12, 2020**

This document provides the Sponsor's responses to CBER's requests (in **Bold**).

ITEM 1:

Important Potential Risk – Vaccine Associated Enhanced Disease (VAED): In your Pharmacovigilance plan (PVP) you describe Vaccine Associated Enhanced Disease (VAED) as an important potential risk but go on to only include the subset of Vaccine Associated Enhanced Respiratory Disease (VAERD) in your PVP table. We assume the intent is to monitor both VAED/VAERD as important potential risks. Please confirm and revise your PVP table to include VAED/VAERD.

Sponsor Response:

The Sponsor will monitor both VAED/VAERD as important potential risks. The revised [Table 2](#) of mRNA-1273 Summary of Safety Concerns is below.

Table 2: mRNA-1273 Summary of Safety Concerns

Summary of Safety Concerns	
Important Identified Risks	None
Important Potential Risks	Vaccine associated enhanced disease Vaccine associated enhanced respiratory disease Anaphylactic reactions (including anaphylaxis)
Missing Information	Pregnant and breast-feeding women Use in the pediatric population Long-term safety Long-term effectiveness Immunogenicity in subjects with immunosuppression Concomitant administration with non-COVID vaccines (e.g. seasonal flu vaccine)

ITEM 2:

Injection site reactions after Day 7: In your Clinical Summary, you describe “Delayed Injection Site Reactions” reported after day 7 and state that the vast majority were solicited local Adverse Reactions with a duration beyond day 7. Please provide data on the subset of subjects who experienced delayed injection site reactions with a start date after day 7, including the case narratives associated with these injection site reactions.

Sponsor Response:

In our module 2.5 clinical summary section 2.5.5.1.2.6.3.2 Delayed Injection Site Reactions based on data snapshot 1 (11-Nov-2020), the tables provided are the summary of solicited adverse reaction persisting beyond 7 days. These were based on solicited adverse reaction data with onset within 7 days of injections.

In response to IR#11 Item 7 (EUA27073 SN013), a summary table of solicited adverse reactions (local and systemic) with day of onset after Day 7 was provided using data collected on the AE eCRF form based on data snapshots as of 11-Nov-2020. Please note eDiary is used to capture solicited adverse reactions started within 7 days of injections. As noted in our response, the tables provided summarized verbatim terms captured as unsolicited AE that were mapped to MedDRA Preferred Terms reflecting the solicited adverse reactions collected by eDiary during the 7 day period after dosing.

In response to this current information request, we are providing subject level data (per subject per event) for those who reported these local solicited adverse reactions (pain, erythema, and swelling) with onset on day 8 and later (relative to the date of vaccination) based on data snapshot 1 (11-Nov-2020) (see appendix included in this submission).